Ceyssens Pieter-Jan, Soetaert Karine, Timke Markus, Van den Bossche An, Sparbier Katrin, De Cremer Koen, Kostrzewa Markus, Hendrickx Marijke, Mathys Vanessa
National Reference Center for Tuberculosis and Mycobacteria, Scientific Institute of Public Health (WIV-ISP), Brussels, Belgium.
Bruker Daltonik GmbH, Bremen, Germany.
J Clin Microbiol. 2017 Feb;55(2):624-634. doi: 10.1128/JCM.02089-16. Epub 2016 Dec 21.
Species identification and drug susceptibility testing (DST) of mycobacteria are important yet complex processes traditionally reserved for reference laboratories. Recent technical improvements in matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has started to facilitate routine mycobacterial identifications in clinical laboratories. In this paper, we investigate the possibility of performing phenotypic MALDI-based DST in mycobacteriology using the recently described MALDI Biotyper antibiotic susceptibility test rapid assay (MBT-ASTRA). We randomly selected 72 clinical Mycobacterium tuberculosis and nontuberculous mycobacterial (NTM) strains, subjected them to MBT-ASTRA methodology, and compared its results to current gold-standard methods. Drug susceptibility was tested for rifampin, isoniazid, linezolid, and ethambutol (M. tuberculosis, n = 39), and clarithromycin and rifabutin (NTM, n = 33). Combined species identification was performed using the Biotyper Mycobacteria Library 4.0. Mycobacterium-specific MBT-ASTRA parameters were derived (calculation window, m/z 5,000 to 13,000, area under the curve [AUC] of >0.015, relative growth [RG] of <0.5; see the text for details). Using these settings, MBT-ASTRA analyses returned 175/177 M. tuberculosis and 65/66 NTM drug resistance profiles which corresponded to standard testing results. Turnaround times were not significantly different in M. tuberculosis testing, but the MBT-ASTRA method delivered on average a week faster than routine DST in NTM. Databases searches returned 90.4% correct species-level identifications, which increased to 98.6% when score thresholds were lowered to 1.65. In conclusion, the MBT-ASTRA technology holds promise to facilitate and fasten mycobacterial DST and to combine it directly with high-confidence species-level identifications. Given the ease of interpretation, its application in NTM typing might be the first in finding its way to current diagnostic workflows. However, further validations and automation are required before routine implementation can be envisioned.
分枝杆菌的菌种鉴定和药敏试验(DST)是重要但复杂的过程,传统上由参考实验室进行。基质辅助激光解吸电离飞行时间质谱(MALDI-TOF MS)的最新技术改进已开始推动临床实验室对分枝杆菌进行常规鉴定。在本文中,我们研究了使用最近描述的MALDI Biotyper抗生素药敏试验快速检测法(MBT-ASTRA)在分枝杆菌学中进行基于MALDI的表型DST的可能性。我们随机选择了72株临床结核分枝杆菌和非结核分枝杆菌(NTM)菌株,采用MBT-ASTRA方法对其进行检测,并将结果与当前的金标准方法进行比较。对利福平、异烟肼、利奈唑胺和乙胺丁醇(结核分枝杆菌,n = 39)以及克拉霉素和利福布汀(NTM,n = 33)进行药敏试验。使用Biotyper分枝杆菌文库4.0进行联合菌种鉴定。得出了分枝杆菌特异性的MBT-ASTRA参数(计算窗口,m/z 5,000至13,000,曲线下面积[AUC] >0.015,相对生长率[RG] <0.5;详情见正文)。使用这些设置,MBT-ASTRA分析得出了175/177例结核分枝杆菌和65/66例NTM的耐药谱,与标准检测结果相符。结核分枝杆菌检测的周转时间没有显著差异,但MBT-ASTRA方法在NTM检测中平均比常规DST快一周。数据库搜索得出90.4%的正确菌种水平鉴定结果,当评分阈值降至1.65时,这一比例提高到了98.6%。总之,MBT-ASTRA技术有望促进和加快分枝杆菌DST,并将其直接与高可信度的菌种水平鉴定相结合。鉴于其易于解读,它在NTM分型中的应用可能首先会进入当前的诊断工作流程。然而,在考虑常规实施之前,还需要进一步验证和自动化。